Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial

BACKGROUND: Results of our previous study showed high objective response but short-term activity of apatinib in advanced osteosarcoma. We aimed to investigate the activity of apatinib in combination with camrelizumab in patients with inoperable high-grade osteosarcoma progressing after chemotherapy....

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Lu, Xu, Jie, Sun, Xin, Guo, Wei, Gu, Jin, Liu, Kuisheng, Zheng, Bingxin, Ren, Tingting, Huang, Yi, Tang, Xiaodong, Yan, Taiqiang, Yang, Rongli, Sun, Kunkun, Shen, Danhua, Li, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223462/
https://www.ncbi.nlm.nih.gov/pubmed/32376724
http://dx.doi.org/10.1136/jitc-2020-000798

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223462/
https://www.ncbi.nlm.nih.gov/pubmed/32376724
http://dx.doi.org/10.1136/jitc-2020-000798

Ejemplares similares